"IM iD" eally treating multiple myeloma

Blood

Volumn 121, Issue 11, 2013, Pages 1926-1928

  Lacy, Martha Q ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CLARITHROMYCIN; DEXAMETHASONE; IMMUNOMODULATING AGENT; LENALIDOMIDE; POMALIDOMIDE; PROTEASOME INHIBITOR; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; PYRAZINE DERIVATIVE;

BONE MARROW SUPPRESSION; CROSS RESISTANCE; HUMAN; IMMUNOMODULATION; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); DRUG EFFECT; DRUG RESISTANCE; FEMALE; MALE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; PYRAZINES; THALIDOMIDE;

MLCS; MLOWN;

EID: 84877631769     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-476267     Document Type: Note

References (13)

1. Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low dose dexamethasone is active and well tolerated in bortezomib and lenalidomide refractory multiple myeloma: IFM 2009-02. Blood. 2013;121(11):1968-1975.
2. Richardson PG, Siegel D, Baz R, et al. Phase I study of pomalidomide MTD, safety and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013;121(11): 1961-1967. Prepublished on 2012/12/18 as DOI 10.1182/blood-2012-08-450742.
3. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5): 2516-2520.
4. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2012;26(1):149-157. Prepublished on 2011/07/30 as DOI 10.1038/leu.2011.196.
5. Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011;118(11): 2970-2975. Prepublished on 2011/06/22 as DOI blood-2011-04-348896 [pii]10.1182/blood-2011-04-348896.
6. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009;27(30):5008-5014. Prepublished on 2009/09/02 as DOI JCO.2009.23.6802 [pii] 10.1200/JCO.2009.23.6802.
7. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010; 24(11):1934-1939. Prepublished on 2010/09/10 as DOI leu2010190 [pii]10.1038/leu.2010.190.
8. Leleu X, Attal M, Arnulf B, et al. High response rates to pomalidomide and dexamethasone in patients with refractory myeloma, final analysis of IFM 2009-02. ASH Annual Meeting Abstracts. 2011;118(21):812.
9. Schuster SR, Kortuem KM, Zhu YX, et al. Cereblon expression predicts response, progression free and overall survival after pomalidomide and dexamethasone therapy in multiple myeloma. ASH Annual Meeting Abstracts. 2012; 120(21):194.
10. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004;22(16):3269-3276.
11. Streetly MJ, Gyertson K, Daniel Y, et al. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol. 2008;141(1):41-51.
12. Mark TM, Boyer A, Rossi AC, et al. ClaPD (clarithromycin, pomalidomide, dexamethasone) therapy in relapsed or refractory multiple myeloma. ASH Annual Meeting Abstracts. 2012;120(21):77.
13. Lacy MQ, Kumar SK, LaPlant BR, et al. Pomalidomide plus low-dose dexamethasone (Pom/Dex) in relapsed myeloma: long term follow up and factors predicing outcome in 345 patients. ASH Annual Meeting Abstracts. 2012;120(21):201.